Xiuning Le, MD PhD
Xiuning Le MD PhD is an Associate Professor Term-Tenure in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas M.D. Anderson Cancer Center.
Dr. Le is an accomplished clinical investigator and translational research with an expertise in oncogene-driven non-small cell lung cancer. She is leading over 20 trials as key investigators. She has led clinical trials resulted in FDA approval of novel targeted therapy and changed the standard of care. Dr. Le is also active in translational research collaborating with bioinformatics and basic researchers. She has published more than 60 articles in the field of lung cancer, including high-impact journals, such as New England Journal of Medicine, Nature, Cancer Discovery, Journal of Clinical Oncology and others.
Dr. Le has received numerous grants and awards, including nationally prestigious awards for clinical investigators, such as ASCO Young Investigator Award (YIA), SU2C-TVF Convergence Program, ASCO Career Development Award (CDA), Paul Calabresi (NIH K12), V Foundation Clinical Investigator Award, and Damon Runyon Clinical Investigator Award. She serves as a member of Southwest Oncology Group (SWOG) and advisory panelist for Cancer.Net (ASCO). In 2023 ASCO annual meeting, Dr. Le was invited as a faculty discussant for metastatic lung cancer section.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AstraZenecaDate added:09/01/2023Date updated:09/21/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:EMD SeronoDate added:09/01/2023Date updated:09/21/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:RegeneronDate added:09/01/2023Date updated:09/21/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:JanssenDate added:09/01/2023Date updated:09/21/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:DaiichiDate added:09/01/2023Date updated:09/21/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AbionDate added:09/01/2023Date updated:09/21/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AbbvieDate added:09/01/2023Date updated:09/21/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:BlueprintDate added:09/01/2023Date updated:09/21/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:SystImmuneDate added:09/01/2023Date updated:09/21/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:TeligeneDate added:09/01/2023Date updated:09/21/2024